This bill makes it easier for suppliers and buyers to use a standardized common name for Stenotomus chrysops, at the cost of narrowing FDA enforcement authority and increasing the risk of misleading or inconsistent seafood labeling.
Small seafood sellers and retailers can label Stenotomus chrysops as "Golden Sea Bream" without FDA enforcement risk, reducing regulatory uncertainty and compliance costs for those businesses.
Seafood consumers will find Stenotomus chrysops more easily because it can be marketed under a standardized common name, improving availability and purchasing convenience.
Limiting FDA enforcement in this specific naming case could create a precedent that weakens regulatory oversight of seafood naming more broadly, increasing the risk of fraud and reducing consumer protections.
Consumers may be misled if the label "Golden Sea Bream" is applied to other species, causing people to buy a different fish than they expect and undermining informed choice.
Based on analysis of 2 sections of legislative text.
Allows the market name "Golden Sea Bream" for Stenotomus chrysops and bars FDA enforcement based solely on that labeling.
Introduced March 4, 2025 by Seth Magaziner · Last progress March 4, 2025
Prohibits the Food and Drug Administration from treating seafood from the species Stenotomus chrysops as misbranded, adulterated, or otherwise in violation of the Federal Food, Drug, and Cosmetic Act solely because it is labeled or marketed using the name "Golden Sea Bream." The effect is to authorize use of "Golden Sea Bream" as an acceptable market name and prevent FDA enforcement actions based only on that labeling choice. The provision does not change other labeling or safety requirements: FDA may still take action for other violations (for example, false claims, contamination, or other misbranding reasons).